| Literature DB >> 34233968 |
Tao Xu1, You Wang1, Jinxian Yuan1, Yangmei Chen1, Haiyan Luo2.
Abstract
OBJECTIVE: Contrast extravasation (CE) after endovascular therapy (EVT) is commonly present in acute ischaemic stroke (AIS) patients. Substantial uncertainties remain about the relationship between CE and the outcomes of EVT in patients with AIS. Therefore, we aimed to evaluate this association.Entities:
Keywords: interventional radiology; neuroradiology; stroke; stroke medicine
Year: 2021 PMID: 34233968 PMCID: PMC8264910 DOI: 10.1136/bmjopen-2020-044917
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
The assessment strategies of contrast extravasation and haemorrhage after EVT
| Assessment methods | Definition of CE | Definition of haemorrhage | Included studies |
| NECT immediately after EVT and a follow-up NECT, MRI-GRE or MRI-SWI at 24 hours after EVT | CE was defined as the presence of high density on NECT immediately after EVT, but with no longer discernible high density on 24 hours follow-up NECT after EVT or with no hyposignal on 24 hours follow-up MRI-GRE and MRI-SWI after EVT | Haemorrhage was defined as the presence of high density on NECT immediately after EVT, with high density on 24 hours follow-up NECT after EVT or with hyposignal on 24 hours follow-up MRI-GRE and MRI-SWI after EVT | Ref |
| Dual-energy CT immediately after EVT | CE was defined as the high density on MIX and IOM, but with no high density of corresponding areas on VNC | Haemorrhage was defined as the high density on MIX and VNC, but with no high density of corresponding areas on IOM | Ref |
CE, contrast extravasation; EVT, endovascular therapy; GRE, T2-weighted gradient-recall echo imaging; IOM, iodine overlay maps; MIX, mixed energy images; NECT, non-enhanced computed tomography; SWI, susceptibility-weighted imaging; VNC, virtual non-contrast-enhanced.
Figure 1Flow chart of the literature search process.
Characteristics of the studies included in the meta-analysis
| First author, year of publication | Country | Participants inclusion period | Study design | Primary methods of EVT | Vascular lesion location | Age, year/men, %/No. in cohort | Outcomes of EVT |
| Kim | South Korea | 2012–2019 | R | SR, AT and IA | ACC | NA/54.9%/145 | ICH and sICH |
| Chen | China | 2016–2019 | R | SR, AP and IA | ACC (ICA and MCA) | 63.1%±11.7/75.9%/166 | Poor functional outcomes at discharge and at 3 months; mortality at discharge and at 3 months; ICH and sICH |
| Xu | China | 2014–2018 | P | SR | NA | 69.8%±11.7/58.6%/198 | ICH |
| Sun | China | 2016–2018 | R | SR | PCA | 60.9%±10.6/82.4%/108 | Poor functional outcomes at 3 months |
| Chen | China | 2015–2016 | R | SR | ACC | NA/54.9%/82 | Poor functional outcomes at 3 months; ICH and sICH |
| An | China | 2013–2017 | P | SR | ACC and PCC | 61.3%±12.8/72%/180 | Poor functional outcomes at 3 months; mortality at 3 months; ICH and sICH |
| Shi | USA | NA | R | SR, AT and IA | ACC | NA/42.9%/210 | Poor functional outcomes at discharge; mortality at discharge; ICH |
| Renú | Spain | 2010–2013 | P | SR | NA | NA/47.7%/132 | Poor functional outcomes at 3 months; ICH |
| Kim | South Korea | 2007–2014 | R | SR, AT and IA | ACC | NA/50.0%/56 | Poor functional outcomes at discharge; ICH and sICH |
| Rouchaud | France | 2009–2011 | R | SR | ACC and PCC | 63.0 (31.0–90.0)/58.7%/63 | Poor functional outcomes at 3 months; mortality at 3 months; ICH |
| Nikoubashman | Germany | 2010–2013 | R | SR, AT and IA | ACC | 71.2%±15.4/52.2%/113 | Poor functional outcomes at discharge and at 3 months; ICH and sICH |
| Desilles | France | 2007–2011 | P | SR | NA | 63.0/51.8%/220 | Poor functional outcomes at 3 months; mortality at 3 months; ICH and sICH |
| Kim | South Korea | 2007–2010 | R | SR, AT and IA | ACC and PCC | 64.9%±14.43/55.9%/68 | Poor functional outcomes at 3 months; mortality at 3 months; sICH |
| Jang | South Korea | 1999–2004 | R | IA | ACC | 64.7%±11.5/67.0%/94 | ICH |
| Yoon | South Korea | 1995–2002 | R | IA | ACC | NA/56.5%/62 | Poor functional outcomes at 3 months; ICH and sICH |
ACC, anterior cerebral circulation; AP, angioplasty; AT, aspiration technique; EVT, endovascular therapy; IA, intra-arterial thrombolysis; ICH, intracranial haemorrhage; NA, not available; P, prospective; PCC, posterior cerebral circulation; R, retrospective; sICH, symptomatic intracranial haemorrhage; SR, stent retriever.
Figure 2Summary of ORs for the relationships between contrast extravasation (CE) and poor functional outcomes at discharge and 90 days. Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was associated with higher risks of poor functional outcome at discharge (heterogeneity test: I2=0.0%, 95% CI 0.00 to 0.83) and poor functional outcome at 90 days (heterogeneity test: I2=73.2%, 95% CI 0.50 to 0.86).
Figure 3Summary of ORs for the relationships between contrast extravasation (CE) and in-hospital mortality and 90-day mortality. Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was not associated with in-hospital mortality (heterogeneity test: I2=66.0%, 95% CI −0.50 to 0.92) or 90-day mortality (heterogeneity test: I2=25.6%, 95% CI −0.85 to 0.70).
Figure 4Summary of ORs for the relationships between contrast extravasation (CE) and risks for intracranial haemorrhage (ICH) and symptomatic ICH (sICH). Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was related to higher risks of post-EVT ICH (heterogeneity test: I2=78.8%, 95% CI 0.64 to 0.87) and sICH (heterogeneity test: I2=0.0%, 95% CI −4.30 to 0.67). EVT, endovascular therapy.